Stockscreener 앱 받기
0.8721
3.35%
-0.0302
시간 외 거래:
.89
0.0179
+2.05%
전일 마감가:
$0.9023
열려 있는:
$0.93
하루 거래량:
1.05M
Relative Volume:
0.66
시가총액:
$83.56M
수익:
-
순이익/손실:
$-93.61M
주가수익비율:
-0.4133
EPS:
-2.11
순현금흐름:
$-71.16M
1주 성능:
-6.38%
1개월 성능:
+5.17%
6개월 성능:
-9.22%
1년 성능:
-34.92%
1일 변동 폭
$0.83
$0.938
1주일 범위
$0.83
$1.01
52주 변동 폭
$0.561
$2.11
Immunic Inc Stock (IMUX) Company Profile
명칭
Immunic Inc
전화
(332) 255-9818
주소
1200 AVENUE OF THE AMERICAS, NEW YORK
IMUX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.8721 | 93.84M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-25 | 개시 | William Blair | Outperform |
| 2024-11-25 | 개시 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-27 | 개시 | B. Riley Securities | Buy |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2021-04-15 | 개시 | Aegis Capital | Buy |
| 2021-03-24 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-08-07 | 재개 | ROTH Capital | Buy |
| 2020-07-20 | 개시 | BMO Capital Markets | Outperform |
| 2020-06-05 | 개시 | Wedbush | Outperform |
| 2020-05-11 | 개시 | H.C. Wainwright | Buy |
| 2020-03-25 | 개시 | ROTH Capital | Buy |
| 2019-07-11 | 개시 | Chardan Capital Markets | Buy |
모두보기
Immunic Inc 주식(IMUX)의 최신 뉴스
Is Immunic Inc. stock a value trapInvestment Timing Signals - thegnnews.com
Technical signs of recovery in Immunic Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
Will Immunic Inc. price bounce be sustainableFree Smart Trade Plans With Risk Protection - Newser
Intraday pattern recognizer results for Immunic Inc.Free Early Entry Tips With Low Risk Zone - Newser
Immunic reports promising Phase 2 data for lead drug candidate in progressive MSICYMI - Proactive financial news
Is a relief rally coming for Immunic Inc. holdersConservative Investment Setup and Risk Analysis - Newser
Immunic: Q2 Earnings Snapshot - Connecticut Post
Immunic, Inc. Advances Multiple Sclerosis Drug Trials - TipRanks
Small cap wrap: Immunic, Nextech3D.ai, EDM Resources, Alvopetro… - Proactive financial news
Immunic Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Immunic CEO on strong Q2 progress with vidofludimus calcium trials for MS - Proactive financial news
Immunic advances MS drug program with Phase 3 trials fully enrolled - Proactive Investors
Immunic Advances Phase 3 Trials and Financial Health - TipRanks
Biotech Immunic Q2 net loss widens, flags need to raise cash - MarketScreener
Immunic, Inc.: A High-Potential Biotech Play in the MS and GI Therapeutics Space - AInvest
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Ariva
Immunic (IMUX) to Release Quarterly Earnings on Thursday - Defense World
Immunic Inc. Stock Analysis and ForecastBreakout profit opportunities - Jammu Links News
When is Immunic Inc. stock expected to show significant growthMarket-crushing stock picks - Jammu Links News
How does Immunic Inc. compare to its industry peersMaximize gains with proven stock analysis - Jammu Links News
What is the dividend policy of Immunic Inc. stockMaximize returns with strategic portfolio planning - Jammu Links News
Should I hold or sell Immunic Inc. stock in 2025Invest confidently with real-time data analysis - Jammu Links News
What is the risk reward ratio of investing in Immunic Inc. stockSuperior profit margins - Jammu Links News
What are analysts’ price targets for Immunic Inc. in the next 12 monthsTrack high-yield stocks before they peak - Jammu Links News
What institutional investors are buying Immunic Inc. stockUnstoppable investment returns - Jammu Links News
What drives Immunic Inc. stock priceGain access to exclusive stock analysis - Jammu Links News
Is it the right time to buy Immunic Inc. stockProven strategies for superior portfolio growth - Jammu Links News
Is Immunic Inc. a growth stock or a value stockBuild wealth faster with consistent investment plans - Jammu Links News
Immunic, Inc. (NASDAQ:IMUX) Receives $7.50 Consensus Target Price from Brokerages - Defense World
Published on: 2025-08-03 05:26:52 - Jammu Links News
How volatile is Immunic Inc. stock compared to the marketTurbocharged investment results - Jammu Links News
How Immunic Inc. stock performs during market volatilityAccurate Forecast System with AI Support - Newser
Why is Immunic Inc. stock attracting strong analyst attentionBreakout Stocks Opportunities That Work - jammulinksnews.com
Why Immunic Inc. stock attracts strong analyst attentionDaily Chart Pattern Stock Forecast Shows Bullish Setup - beatles.ru
Multiple Sclerosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Scie - Menafn
What is Immunic Inc. company’s growth strategyBreakthrough profit margins - Jammu Links News
What are the technical indicators suggesting about Immunic Inc.Free Consultation - jammulinksnews.com
Immunic Inc (IMUX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):